ArticleFrontiers in medicine2026
Upadacitinib in refractory acquired reactive perforating collagenosis with atopic dermatitis and chronic kidney disease: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis characterized by transepidermal elimination of degenerated collagen fibers. It frequently develops secondary to systemic comorbidities, including diabetes mellitus, chronic kidney disease (CKD), and atopic dermatitis (AD), which limit therapeutic options and contribute to unpredictable outcomes. Here, we report a case of ARPC with concurrent AD in a patient with type 2 diabetes mellitus and stage 4 CKD, who experienced acute paradoxical exacerbation within 24 h of dupilumab initiation and achieved sustained remission with upadacitinib. Case summary: A 72-year-old male presented with a 5-year history of recurrent generalized pruritus, erythema, papules, and nodules. Despite treatment with glucocorticoids and anti-allergic medications, the skin lesions remained poorly controlled. Histopathological examination revealed transepidermal elimination of collagen fibers through the ulcer bed into the underlying dermis. Verhoeff-van Gieson staining demonstrated collagen fibers traversing the ulceration. The patient was diagnosed with ARPC. He had poorly controlled comorbidities, including AD, type 2 diabetes mellitus, and stage 4 CKD. Dupilumab was administered as a single 600 mg dose but was discontinued due to paradoxical worsening within 24 h. Following two years of recurrent relapses despite systemic corticosteroids, antihistamines, and thalidomide, oral upadacitinib 15 mg once daily was initiated, with marked resolution of skin lesions and pruritus. After 9 months of treatment, upadacitinib was discontinued, and the patient remained in stable remission at 1-year follow-up. No adverse effects were observed, and renal function remained stable throughout treatment. Conclusion: This case suggests that upadacitinib is a promising salvage therapy for refractory ARPC, particularly after failure of Th2-targeted biologics. Its favorable safety profile at the standard dose without adjustment in stage 4 CKD supports its use in patients with complex comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.